Tag:
AstraZeneca
Latest Headlines
Latest Headlines
UPDATED: AZ stokes $45B sales hopes with expanded approval for breast cancer drug Faslodex
AstraZeneca scored FDA approval for an expanded indication for its breast cancer drug Faslodex, a win for the company as it looks to cancer drugs to boost its revenues by 2023.
Does Roche's IL-13 setback in PhIII signal similar trouble ahead for AstraZeneca?
Trouble with Roche's late-stage IL-13 asthma drug lebrikizumab raises questions about just how effective this R&D; strategy will be for the crowded field of players in severe asthma. More specifically, Roche's troubles may foreshadow issues ahead for AstraZeneca's tralokinumab, another IL-13 player that's faced setbacks in the clinic.
AstraZeneca funds 'robotic pill' company Rani Therapeutics in pursuit of oral biologics
San Jose, CA's Rani Therapeutics, developer of a "robotic pill" to convert injectable drugs into oral pills, announced that it has closed its latest funding round, putting the company's VC haul above $70 million as it seeks to expand the team, add new facilities and scale up manufacturing.
AstraZeneca pawning off rights to more drugs to keep the cash coming in
AstraZeneca CEO Pascal Soriot is back to pawning off some stuff from the back of the closet to make the monthly rent. The U.K. drugmaker this time is selling the rights to a couple of heart drugs to a Chinese company, raising $500 million while giving up what last year amounted to $246 million in revenue.
UPDATED: In a setback, AstraZeneca's immunotherapy tremelimumab flunks mesothelioma test
Just days after AstraZeneca reported a success for a combination study of durvalumab and tremelimumab, the pharma giant has been forced to concede that the CTLA-4 drug tremelimumab flunked a solo challenge for mesothelioma.
Linchpins of British biopharma throw weight behind campaign to stay in the EU
If the United Kingdom votes to exit the European Union, AstraZeneca CEO Pascal Soriot, GlaxoSmithKline R&D; Chief Patrick Vallance and others predict it will cause disruption, expense and significant regulatory burdens, while also deterring inward investment.
AstraZeneca bags EU approval for gout drug Zurampic as it eyes $500M in sales
AstraZeneca snagged EU approval for its gout drug Zurampic, a few months after the med got an FDA green light. The regulatory blessing helps the U.K. drugmaker as it looks to new meds to fill the void for its top sellers Crestor and Nexium, which are facing increased generic competition.
Biotech vet grabs AstraZeneca drug, $26M to start building Corvidia
Three years after Michael Davidson and his colleagues sold the omega-3 drug Epanova to AstraZeneca in the $443 million Omthera buyout, the biotech exec has rounded up some fresh support from a seasoned ally in the venture world to begin building a new biotech focused on cardiovascular disease.
Roche and AstraZeneca snag 'breakthrough' tags for a pair of blockbusters in waiting
Roche and AstraZeneca picked up FDA breakthrough therapy designations for their top pipeline assets, moving forward in multiple sclerosis and cancer with treatments tabbed as potential blockbusters.
AstraZeneca and Daiichi Sankyo field backlash over Super Bowl OIC awareness ad
A parade of politicians, physicians and pundits have criticized a Super Bowl commercial intended to stimulate awareness of opioid-induced constipation, linking the campaign to the opioid prescription drug addiction problem in the U.S. and forcing AstraZeneca and Daiichi Sankyo, which market the OIC relief drug Movantik, to defend it.
